Page 69 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 69
Parallel Session: Non-invasive marker of liver disease: Management (Cont.) Strauss 1
ABSTRACT THE UK-PBC RISK SCORE: DERIVATION AND
O022 VALIDATION OF A RISK SCORE TO PREDICT LIVER
17:30 - 17:45 EVENTS IN THE UK-PBC RESEARCH COHORT
Marco Carbone, The United Kingdom
ABSTRACT REPEATED MEASUREMENT OF NON-INVASIVE SCIENTIFIC PROGRAMME
O023 FIBROSIS MARKERS TO ASSESS HEPATITIS C
17:45 - 18:00 PROGRESSION AND CLINICAL OUTCOMES
Sabela Lens, Spain
Parallel Session: Fatty liver disease: Clinical Strauss 3
Chairs:
Helena Cortez-Pinto, Portugal
Giulio Marchesini, Italy
ABSTRACT HERITABILITY OF HEPATIC FIBROSIS AND HEPATIC
O040 STEATOSIS, AND THEIR SHARED GENE EFFECTS WITH
16:00 - 16:15 METABOLIC TRAITS IN NAFLD: A PROSPECTIVE TWIN
STUDY
ABSTRACT Rohit Loomba, The United States
O041
16:15 - 16:30 INCREASING ASSOCIATION OF NON-ALCOHOLIC FATTY
LIVER DISEASE (NAFLD) WITH HEPATOCELLULAR
ABSTRACT CARCINOMA IN THE UNITED STATES: DATA FROM
O042 SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS
16:30 - 16:45 (SEER)-MEDICARE REGISTRIES (2004-2009)
Zobair Younossi, The United States
ABSTRACT
O043 WEIGHT LOSS INTENSITY IS STRONGLY ASSOCIATED
16:45 - 17:00 TO IMPROVEMENT OF HISTOLOGICAL PARAMETERS
IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
AFTER 52 WEEKS OF LIFESTYLE MODIFICATION
Eduardo Vilar-Gomez, Spain
THE FNDC5 RS3480 IS PROTECTIVE ON THE STEATOSIS
AND FIBROSIS IN PATIENTS WITH NAFLD
Rodolphe Anty, France
Vienna, Austria • April 22–26, 2015 69
ABSTRACT THE UK-PBC RISK SCORE: DERIVATION AND
O022 VALIDATION OF A RISK SCORE TO PREDICT LIVER
17:30 - 17:45 EVENTS IN THE UK-PBC RESEARCH COHORT
Marco Carbone, The United Kingdom
ABSTRACT REPEATED MEASUREMENT OF NON-INVASIVE SCIENTIFIC PROGRAMME
O023 FIBROSIS MARKERS TO ASSESS HEPATITIS C
17:45 - 18:00 PROGRESSION AND CLINICAL OUTCOMES
Sabela Lens, Spain
Parallel Session: Fatty liver disease: Clinical Strauss 3
Chairs:
Helena Cortez-Pinto, Portugal
Giulio Marchesini, Italy
ABSTRACT HERITABILITY OF HEPATIC FIBROSIS AND HEPATIC
O040 STEATOSIS, AND THEIR SHARED GENE EFFECTS WITH
16:00 - 16:15 METABOLIC TRAITS IN NAFLD: A PROSPECTIVE TWIN
STUDY
ABSTRACT Rohit Loomba, The United States
O041
16:15 - 16:30 INCREASING ASSOCIATION OF NON-ALCOHOLIC FATTY
LIVER DISEASE (NAFLD) WITH HEPATOCELLULAR
ABSTRACT CARCINOMA IN THE UNITED STATES: DATA FROM
O042 SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS
16:30 - 16:45 (SEER)-MEDICARE REGISTRIES (2004-2009)
Zobair Younossi, The United States
ABSTRACT
O043 WEIGHT LOSS INTENSITY IS STRONGLY ASSOCIATED
16:45 - 17:00 TO IMPROVEMENT OF HISTOLOGICAL PARAMETERS
IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
AFTER 52 WEEKS OF LIFESTYLE MODIFICATION
Eduardo Vilar-Gomez, Spain
THE FNDC5 RS3480 IS PROTECTIVE ON THE STEATOSIS
AND FIBROSIS IN PATIENTS WITH NAFLD
Rodolphe Anty, France
Vienna, Austria • April 22–26, 2015 69
